There is evidence that cytotoxic T lymphocytes (T cells) participate in controlling tumor growth and that they can be harnessed to use the body's immune system to treat cancer. One study investigated the use of a T cell-engaging antibody, blinatumomab, to recruit T cells to control tumor growth. The data below are T cell counts (1000 per microliter) at baseline (beginning of the study) and after 20 days on blinatumomab for 6 subjects in the study. The difference (after 20 days minus baseline) is the response variable. Baseline 0.04 0.02 0 0.02 0.38 0.31
After 20 days 0.18 0.37 1.1 0 0 0.34
Difference 0.14 0.35 1.1 -0.02 -0.38 0.03
Do the data give evidence at the 2% level that the mean count of T cells is higher after 20 days on blinatumomab? The test statistic is t = (±0.001)?